United States · Series D startup
6 rounds we have observed, with the 4 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$61Mraised across 6 rounds since 2011, from 6 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
No investor was named in the report.
From a historical funding record
From a historical funding recordSEC filing: $5.7M sold, first sale Mar 2014
Reported by finsmes.comSEC filing: $3.7M sold, first sale Mar 2013
From a historical funding recordSEC filing: $3.7M sold, first sale Mar 2013
ShireReported by finsmes.comSEC filing: $9.0M sold, first sale Mar 2012
Reported by neurophage.comSEC filing: $8.4M sold, first sale Feb 2011
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
ShireMérieux DéveloppementMichael GrundmanMissing a round, or an investor who was in one? Tell us.
NeuroPhage Pharmaceuticals's investors include Merieux Developpement, Shire, Mérieux Développement and Michael Grundman.
NeuroPhage Pharmaceuticals has raised $61M across 6 rounds since 2011.
NeuroPhage Pharmaceuticals's most recent round was a Series D of $10M in Jan 2015.
NeuroPhage Pharmaceuticals's largest round on record is $17M (Series D), in Mar 2014.
NeuroPhage Pharmaceuticals's first round on record, in Mar 2011, was backed by Merieux Developpement, Shire and Mérieux Développement.
NeuroPhage Pharmaceuticals's latest named round is a Series D, in Jan 2015.
NeuroPhage Pharmaceuticals is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
